Cargando…

The potential of Atorvastatin for chronic lung diseases therapy

Atorvastatin (ATO) is of the statin class and is used as an orally administered lipid-lowering drug. ATO is a reversible synthetic competitive inhibitor of 3-hydroxy-3-methyl-glutaryl-CoA (HMG-CoA) reductase thus leading to a reduction in cholesterol synthesis. It has recently been demonstrated that...

Descripción completa

Detalles Bibliográficos
Autor principal: Tulbah, Alaa S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7679442/
https://www.ncbi.nlm.nih.gov/pubmed/33250642
http://dx.doi.org/10.1016/j.jsps.2020.08.025
_version_ 1783612343224107008
author Tulbah, Alaa S.
author_facet Tulbah, Alaa S.
author_sort Tulbah, Alaa S.
collection PubMed
description Atorvastatin (ATO) is of the statin class and is used as an orally administered lipid-lowering drug. ATO is a reversible synthetic competitive inhibitor of 3-hydroxy-3-methyl-glutaryl-CoA (HMG-CoA) reductase thus leading to a reduction in cholesterol synthesis. It has recently been demonstrated that ATO has different pharmacological actions, which are unrelated to its lipid-lowering effects and has the ability to treat chronic airway diseases. This paper reviews the potential of ATO as an anti-inflammatory, antioxidant, and anti-proliferative agent after oral or inhaled administration. This paper discusses the advantages and disadvantages of using ATO under conditions associated with those found in the airways. This treatment could potentially be used to support the formulating of ATO as an inhaler for the treatment of chronic respiratory diseases.
format Online
Article
Text
id pubmed-7679442
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-76794422020-11-27 The potential of Atorvastatin for chronic lung diseases therapy Tulbah, Alaa S. Saudi Pharm J Review Atorvastatin (ATO) is of the statin class and is used as an orally administered lipid-lowering drug. ATO is a reversible synthetic competitive inhibitor of 3-hydroxy-3-methyl-glutaryl-CoA (HMG-CoA) reductase thus leading to a reduction in cholesterol synthesis. It has recently been demonstrated that ATO has different pharmacological actions, which are unrelated to its lipid-lowering effects and has the ability to treat chronic airway diseases. This paper reviews the potential of ATO as an anti-inflammatory, antioxidant, and anti-proliferative agent after oral or inhaled administration. This paper discusses the advantages and disadvantages of using ATO under conditions associated with those found in the airways. This treatment could potentially be used to support the formulating of ATO as an inhaler for the treatment of chronic respiratory diseases. Elsevier 2020-11 2020-09-12 /pmc/articles/PMC7679442/ /pubmed/33250642 http://dx.doi.org/10.1016/j.jsps.2020.08.025 Text en © 2020 The Author(s) http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Review
Tulbah, Alaa S.
The potential of Atorvastatin for chronic lung diseases therapy
title The potential of Atorvastatin for chronic lung diseases therapy
title_full The potential of Atorvastatin for chronic lung diseases therapy
title_fullStr The potential of Atorvastatin for chronic lung diseases therapy
title_full_unstemmed The potential of Atorvastatin for chronic lung diseases therapy
title_short The potential of Atorvastatin for chronic lung diseases therapy
title_sort potential of atorvastatin for chronic lung diseases therapy
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7679442/
https://www.ncbi.nlm.nih.gov/pubmed/33250642
http://dx.doi.org/10.1016/j.jsps.2020.08.025
work_keys_str_mv AT tulbahalaas thepotentialofatorvastatinforchroniclungdiseasestherapy
AT tulbahalaas potentialofatorvastatinforchroniclungdiseasestherapy